Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 2, 2008, Pages 159-167

  El Demerdash, Ebtehal ^a   Salam, Omar M Abdel ^b   El Batran, Seham A ^b   Abdallah, Heba M I ^b   Shaffie, Nermeen M ^b  

^a Ain Shams University   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Liver fibrosis; Oxidative stress; Renin angiotensin system inhibitors

Indexed keywords

CARBON TETRACHLORIDE; FOSINOPRIL; GLUTATHIONE; HYDROXYPROLINE; LIPID PEROXIDASE; LISINOPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOSINOPRIL; GLUTATHIONE; HYDROXYPROLINE; LIPID PEROXIDATION; LISINOPRIL; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOSARTAN; MALE; OXIDATIVE STRESS; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 38149078717     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04797.x     Document Type: Article

References (51)

1. Poli G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol. Aspects Med. 2000 21: 49 98.
2. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994 41: 343 8.
3. Murrell GAC, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 1990 265: 659 65.
4. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000 275: 2247 50.
5. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv. Pharmacol. 1997 38: 601 28.
6. Albanis EL, Safadi RL, Friedman SL. Treatment hepatic fibrosis: Almost there. Curr. Gastroenterol. Rep. 2003 5: 48 56.
7. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005 115: 209 18.
8. Bicket DP. Using ACE inhibitors appropriately. Am. Fam. Physician 2002 66: 461 8.
9. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J. Am. Coll. Cardiol. 2001 37: 1461 6.
10. Jahovic N, Ercan F, Gedik N et al. The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats. Regul. Pept. 2005 130: 67 74.
11. Mira ML, Silva MM, Queiros MJ, Manso CF. Angiotensin-converting enzyme inhibitors as oxygen free radical scavengers. Free Radic. Res. Commun. 1993 19: 173 81.
12. Ravati A, Junker V, Kouklei M et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur. J. Pharmacol. 1999 373: 21 33.
13. Kedziora-Kornatowska K. Effect of angiotensin convertase inhibitors and AT1 angiotensin receptor antagonists on the development of oxidative stress in the kidney of diabetic rats. Clin. Chim. Acta 1999 287: 19 27.
14. Massoudy P, Becker BF, Gerlach E. Nitric oxide accounts for postischemic cardioprotection resulting from angiotensin-converting enzyme inhibition: Indirect evidence for a radical scavenger effect in isolated guinea pig heart. J. Cardiovasc. Pharmacol. 1995 25: 440 7.
15. Uhal BD, Gideea C, Bargout R et al. Captopril inhibits apoptosis in human lung epithelial cells: A potential antifibrotic mechanism. Am. J. Physiol. 1998 275: L1013 17.
16. Hebert LA, Falkenhain ME, Nahman Jr. NS et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am. J. Nephrol. 1999 19: 1 6.
17. Paizis G, Cooper ME, Schembri JM et al. Up-regulation of components of the renin angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002 123: 1667 76.
18. 4 in rats. Dig. Dis. Sci. 2004 49: 1589 94.
19. Recknagel RO, Glende EA, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol. Ther. 1989 43: 139 54.
20. 4 cirrhosis in rats: Irreversible histological changes and differentiated functional impairment. J. Hepatol. 1991 12: 110 17.
21. Paget GE, Barens JM. Toxicity tests. In: Laurence DR Bacharach AL (eds). Evaluation of Drug Activities: Pharmacometrics. Academic Press, New York. 1964 135 66.
22. 4-induced liver injury and survival in rats. J. Ethnopharmacol. 1997 56: 59 164.
23. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 1957 28: 56 63.
24. Walter M, Gerade RW. Bilirubin direct/total. Microchem. J. 1970 15: 231 3.
25. Belfield A, Goldberg DM. Revised assay of serum phenyl phosphatase activity using 4-amino-antipyrene. Enzyme 1971 12: 561 73.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979 95: 351 8.
27. Ellman GL. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959 82: 70 7.
28. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 1961 93: 440 7.
29. 4. World. J. Gastroenterol. 2000 6: 540 5.
30. Wong FW, Chan WY, Lee SS. Resistance to carbontetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 1998 153: 109 18.
31. 13C-carbon tetrachloride metabolism in vitro and in vivo. Biochem. Biophys. Res. Commun. 1980 94: 1154 60.
32. Zimmerman HJ, Seeff LB. Enzymes in hepatic disease. In: Goodly EE (ed.). Diagnostic Enzymology. Lea & Febiger, Philadelphia. 1970 24 6.
33. Yokohama S, Yoneda M, Nakamura K, Makino I. Effect of central corticotropin-releasing factor on carbon tetrachloride-induced acute liver injury in rats. Am. J. Physiol. 1999 276: G622 8.
34. 4-induced liver injury in low-protein fed rats. Phytother. Res. 2005 19: 341 5.
35. Ohishi T, Saito H, Tsusaka K et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res. 2001 21: 147 58.
36. Shionoiri H, Naruse M, minamisawa K et al. Fosinopril: Clinical pharmacokinetics and clinical potential. Clin. Pharmacokinet. 1997 32: 460 80.
37. Plaa GL. Chlorinated methanes and liver injury: Highlights of the past 50 years. Annu. Rev. Pharmacol. Toxicol. 2000 40: 42 65.
38. Burk RF, Patel K, Lane JM. Reduced glutathione protection against rat liver microsomal injury by carbon tetrachloride. Biochem. J. 1983 215: 441 5.
39. Szymonik-Lesiuk S, Czechowska G, Stryjecka-Zimmer M et al. Catalase, superoxide dismutase, and glutathione peroxidase activities in various rat tissues after carbon tetrachloride intoxication. J. Hepatobil. Pancreat. Surg. 2003 10: 309 15.
40. Ko KM, Ip SP, Poon MK et al. Effect of a lignan-enriched Fructus schisandrae extract on hepatic glutathione status in rats: Protection against carbon tetrachloride toxicity. Planta Med. 1995 61: 134 7.
41. Farber JL. Xenobiotics, drug metabolism and liver injury. Monogr. Pathol. 1987 28: 43 53.
42. Slater TF. Free-radical mechanisms in tissue injury. Biochem. J. 1984 222: 1 15.
43. Bandyopadhyay U, Das D, Banerjee RK. Reactive oxygen species. Oxidative damage and pathogenesis. Curr. Sci. 1999 77: 658 66.
44. Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J. Gastroenterol. 2005 11: 6684 8.
45. He S, Luo J, Wang Y et al. Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats. World J. Gastroenterol. 2006 12: 3924 8.
46. Cruz CI, Ruiz-Torres P, del Moral RG, Rodriguez-Puyol M, Rodriguez-Puyol D. Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Am. J. Physiol. Renal Physiol. 2000 278: F122 9.
47. Mantle D, Patel VB, Why HJ et al. Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. Clin. Chim. Acta 2000 299: 1 10.
48. Dogan R, Farsak B, Isbir S et al. Protective effect of lisinopril against ischemia-reperfusion injury in isolated guinea pig hearts. J. Cardiovasc. Surg. 2001 42: 43 8.
49. Ala-kokko L, Stenback F, Ryhanen L. Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat. Biochem. J. 1987 246: 503 9.
50. 4-induced hepatic fibrosis. World J. Gastroenterol. 2005 11: 1141 8.
51. Yu CM, Tipoe GL, Wing-Hon Lai K et al. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J. Am. Coll. Cardiol. 2001 38: 1207 15.